Radiotherapy without groin treatment for early stage anal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of omitting preventative radiation to the groin in patients with early stage anal cancer who have normal sentinel node biopsy and PET-CT results. The approach involves administering chemo-radiation treatment while assessing whether avoiding radiation to the groin leads to fewer side effects and improved quality of life. The hypothesis is that patients with early clinical stage node negative anal cancer have a low risk of subclinical inguinal lymph node involvement, which can be accurately determined using PET imaging and sentinel lymph node biopsy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants capable of giving informed consent.
2. Patients must be 18 years of age or older.
3. Patient should have histologically proven primary squamous cell carcinoma.
4. Patients must have early AC, Stage T1-3 N0 M0.
5. No inguinal nodal involvement confirmed by PET imaging and SLNB.
6. No history of prior malignancy other than non-melanoma skin cancer or other malignancy with disease free survival ≥ 5 years.
7. Performance status ECOG 0-2 / Zubrod performance status ≥70.
8. Patient should be eligible for concomitant chemotherapy (e.g. adequate hepatic, renal and bone marrow function).
9. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level \> 40 mIU/mL to confirm menopause.
10. Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly (Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard).
11. Females must not breastfeed during study treatment.
12. Male patients should agree to not donate sperm during study treatment.
13. Absence of any condition hampering compliance with study protocols and follow-up schedule; those conditions should be reviewed with the patient prior to trial registration.

Exclusion Criteria:

1. T1N0 patients going for primary surgery
2. Prior radiation therapy to the pelvis.
3. Pregnancy or lactation.
4. Prior surgical treatment for anal cancer other than biopsy.
5. Prior surgical or chemotherapy treatment for anal cancer.
6. Evidence of distant metastases.
7. Comorbid medical conditions precluding radical treatment at the discretion of Oncologist.
8. Histology other than squamous cell carcinoma or variants.

Where it's running

• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Kurian Joseph, MD — Ahs-Cci
• Study coordinator: Kurian Joseph, MD
• Email: kurian.joseph@ahs.ca
• Phone: 780-432-8755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood ctDNA testing to guide follow-up and treatment for HPV-related cervical and anal canal cancers.

  This study will test whether regular blood tests for HPV ctDNA can guide follow-up and whether giving pembrolizumab after radiotherapy helps people with HPV-related cervical or anal canal cancer who still have positive ctDNA.

  Recruiting Phase 2 Instituto do Cancer do Estado de São Paulo · São Paulo · NCT06640283

• Using targeted radiation therapy for liver tumors that can't be surgically removed

  This study is testing if a special type of radiation therapy can help patients with certain types of cancer who have liver tumors that can't be surgically removed.

  Recruiting Phase 2 University of Sao Paulo · São Paulo, São Paulo · NCT02185443

• Virus-linked Tumor Microenvironment in CancerPatients

  This study tests how viruses influence the tumor environment across several cancers to understand how Treatments might work better.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06471296

• Understanding Extramammary Paget's Disease in Women

  This study looks at women with Extramammary Paget's Disease to see how different treatments work and to learn more about the skin and health in those areas.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT03564483

• Mepilex Lite dressings to treat acute radiation dermatitis of the anal canal

  This trial will try Mepilex Lite dressings to reduce pain and help heal acute radiation skin damage inside the anal canal for adults receiving radiotherapy for rectal cancer.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT06837831

• Comparing two radiation therapies for anal canal cancer with chemotherapy

  This study is testing whether a new type of radiation therapy called proton therapy works better than standard radiation therapy for people with anal canal cancer who are also getting chemotherapy, while trying to reduce side effects.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT06630793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.